Prof. Liu Yingbin (刘颍斌) — Gallbladder Cancer & Biliary Tract Surgery | Renji Hospital, Shanghai Jiao Tong University
For international patients facing a diagnosis of gallbladder cancer, intrahepatic cholangiocarcinoma, or hilar cholangiocarcinoma — among the most challenging and least understood malignancies in oncology — access to a surgeon with both deep subspecialty expertise and a research foundation built on the world's largest disease-specific dataset is rare. Prof. Liu Yingbin (刘颍斌) at Renji Hospital, Shanghai Jiao Tong University School of Medicine, is precisely that specialist. He is China's foremost authority on gallbladder cancer precision diagnosis and treatment, and one of the country's leading experts in complex biliary-pancreatic oncological surgery.
Specialty Focus
- Gallbladder cancer: precision surgical resection, staging, and comprehensive treatment
- Intrahepatic cholangiocarcinoma (iCCA): surgical resection and multimodal management
- Hilar cholangiocarcinoma (Klatskin tumor): complex biliary reconstruction and vascular management
- Distal cholangiocarcinoma and ampullary carcinoma
- Pancreatic cancer: complex surgical resection including Whipple procedure
- Multidisciplinary comprehensive treatment of biliary-pancreatic malignancies
Academic & Clinical Titles
- Chief Physician & Professor, Department of Biliary-Pancreatic Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine
- National High-Level Talent (国家级高层次人才)
- State Council Special Allowance Expert (国务院特殊津贴专家) — one of China's highest recognitions for scientific and technical contribution
- Builder of China's largest multicenter gallbladder cancer single-disease database
- Principal investigator in multiple national research programs on biliary tract malignancies
China's Largest Gallbladder Cancer Database: Why It Matters
Gallbladder cancer is a rare malignancy — rare enough that even experienced hepatobiliary surgeons at major centers may encounter only a handful of cases per year. This rarity creates a fundamental challenge: without large patient cohorts, it is difficult to generate the evidence needed to optimize surgical technique, staging systems, adjuvant therapy selection, and prognostic prediction.
Prof. Liu Yingbin has addressed this challenge directly by building and leading China's largest multicenter gallbladder cancer single-disease database — a research infrastructure that aggregates clinical, pathological, molecular, and outcomes data from patients across multiple Chinese institutions. This database has enabled Prof. Liu's team to conduct research that would be impossible at any single center, generating insights into gallbladder cancer biology, surgical outcomes, and treatment optimization that have shaped national practice.
For patients, this research foundation translates into clinical decisions informed by the largest available evidence base for this rare disease. When Prof. Liu recommends a specific surgical approach, staging workup, or adjuvant treatment strategy, that recommendation is grounded in data from hundreds or thousands of patients — not just the experience of a single institution.
Gallbladder Cancer: A Disease Where Surgical Expertise Is Critical
Gallbladder cancer is one of the most surgically demanding biliary malignancies. The gallbladder's proximity to the liver, bile ducts, portal vein, and hepatic artery means that achieving clear surgical margins often requires complex resections involving partial hepatectomy, bile duct resection with reconstruction, and sometimes vascular resection. The extent of surgery required depends on the T-stage of the tumor, and the decision about how aggressively to resect — balancing oncological completeness against operative risk — requires both technical skill and deep familiarity with the disease's natural history.
Prof. Liu's expertise in standardized surgical resection for gallbladder cancer reflects his research-informed understanding of the relationship between surgical extent and oncological outcomes. His work on the multicenter database has helped define the optimal surgical approach for different stages and anatomical presentations of gallbladder cancer — knowledge that directly informs his operative decision-making.
Cholangiocarcinoma: Intrahepatic and Hilar
Beyond gallbladder cancer, Prof. Liu has extensive expertise in both major subtypes of cholangiocarcinoma:
Intrahepatic cholangiocarcinoma (iCCA) arises within the liver parenchyma and is the second most common primary liver cancer after hepatocellular carcinoma. Surgical resection with adequate margins is the only potentially curative treatment, but many patients present with multifocal disease or vascular involvement that complicates resectability assessment. Prof. Liu's hepatobiliary surgical expertise enables him to evaluate and operate on complex iCCA cases that may be deemed unresectable at lower-volume centers.
Hilar cholangiocarcinoma (Klatskin tumor) arises at the confluence of the left and right hepatic ducts and is one of the most technically demanding biliary malignancies to resect. Achieving R0 resection typically requires major hepatectomy combined with bile duct resection and reconstruction, often with portal vein resection. Preoperative biliary drainage, portal vein embolization to induce future liver remnant hypertrophy, and careful vascular assessment are essential components of the surgical planning process. Prof. Liu's experience with these complex cases is a key differentiator.
Molecular Profiling and Targeted Therapy in Biliary Tract Cancers
The treatment of biliary tract cancers has been transformed by the identification of actionable molecular alterations:
- FGFR2 fusions/rearrangements (present in approximately 10–16% of intrahepatic CCA): targeted by pemigatinib, infigratinib, and futibatinib
- IDH1 mutations (present in approximately 13–20% of intrahepatic CCA): targeted by ivosidenib
- BRAF V600E mutations: targeted by dabrafenib + trametinib combination
- HER2 amplification/overexpression: targeted by trastuzumab-based regimens (more common in gallbladder cancer)
- MSI-H/dMMR: eligible for pembrolizumab immunotherapy
- NTRK fusions, RET fusions: rare but actionable
Comprehensive molecular profiling (NGS panel) is now recommended for all biliary tract cancer patients, as the identification of an actionable alteration can significantly change the treatment plan. Prof. Liu's team integrates molecular profiling into the diagnostic workup and treatment planning process for all biliary tract cancer patients.
Comprehensive Treatment: Beyond Surgery
Prof. Liu's expertise extends beyond surgical resection to the comprehensive management of biliary tract malignancies. For patients with unresectable or metastatic disease, his team coordinates:
- Systemic chemotherapy: gemcitabine + cisplatin (GemCis) remains the standard first-line regimen for advanced biliary tract cancer, with the addition of durvalumab (TOPAZ-1 trial) now incorporated into guidelines
- Second-line chemotherapy: FOLFOX or other platinum-based regimens
- Targeted therapy based on molecular profiling results
- Interventional radiology: biliary stenting for obstruction, TACE or ablation for selected intrahepatic lesions
- Radiation therapy for local control in selected cases
- Clinical trial access for novel agents and combinations
Who Should Consider Consulting Prof. Liu Yingbin
- Patients with gallbladder cancer at any stage seeking surgical evaluation or second opinion
- Patients with intrahepatic or hilar cholangiocarcinoma being evaluated for resectability
- Patients who have been told their biliary tract tumor is unresectable and want a second surgical opinion
- Patients with advanced biliary tract cancer seeking molecular profiling and targeted therapy evaluation
- Patients with pancreatic cancer requiring complex surgical resection
- Patients seeking access to clinical trials for biliary tract malignancies
How CMCS Connects You with Prof. Liu Yingbin
China Medical Concierge Shanghai (CMCS) facilitates access to Prof. Liu Yingbin for international patients with gallbladder cancer, cholangiocarcinoma, and related biliary-pancreatic malignancies. Our team manages the full coordination process — from remote case review and medical record translation to appointment scheduling, interpretation, and in-hospital support.
To begin, patients or their families are encouraged to share available medical records including CT and/or MRI with biliary protocol, pathology reports, molecular profiling results (NGS panel), tumor markers (CA 19-9, CEA, AFP), liver function tests, and prior treatment summaries. Prof. Liu's team can conduct an initial remote resectability assessment before any travel to Shanghai is required.
CMCS provides end-to-end support including:
- Medical record translation (English, Arabic, French, and other languages)
- Remote pre-consultation resectability assessment
- Appointment coordination with Prof. Liu Yingbin's clinic at Renji Hospital
- On-site interpretation during consultations and procedures
- Molecular profiling coordination and targeted therapy eligibility assessment
- Post-consultation summary and follow-up support
Contact CMCS to Connect with Prof. Liu Yingbin
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
CMCS – China Medical Concierge Shanghai connects international patients with Shanghai's leading specialists. We are a health management company, not a hospital. All clinical decisions are made by the treating physician.
0 comments